• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
JIANG Weiwei, ZHANG Lei, SHEN Yan. Analysis of China patent application for the pharmaceutical preparations of artemisinins[J]. Journal of China Pharmaceutical University, 2016, 47(2): 242-246. DOI: 10.11665/j.issn.1000-5048.20160219
Citation: JIANG Weiwei, ZHANG Lei, SHEN Yan. Analysis of China patent application for the pharmaceutical preparations of artemisinins[J]. Journal of China Pharmaceutical University, 2016, 47(2): 242-246. DOI: 10.11665/j.issn.1000-5048.20160219
shu

Analysis of China patent application for the pharmaceutical preparations of artemisinins

More Information
    Graphical Abstract
    • Abstract
  • Artemisinins were reported to have the potential efficacy of anticancer, anti-AIDS, etc. , besides antimalaria. Clinical application of current dosage forms has significant drawbacks, i. e. , poor solubility, high first pass effect, low bioavailability, frequent dosing, low bioavailability, high plasmodium recrudescence rate, etc. To overcome these drawbacks, a hot area of research is to develop novel artemisinin dosage forms by applying new preparation technology. Here we summarized the related patents application technology in order to provide helpful references and recommendations on the development of artemisinin dosage forms, patents protection and layout of intellectual properties to the domestic R&D institutes and pharmaceutical manufacturers.
    • FullText(HTML)
    • References (14)
  • [1]
    Efferth T,Oesch F.Oxidative stress response of tumor cells:microar-ray-based comparison between artemisinins and anthracyclines[J].Biochem Pharmacol,2004,68(1):3-10.
    [2]
    Zhu YH.Advances in artemisinin[J].Sci Technol Rev(科技导报),2015,33(20):36-41.
    [3]
    Chen YY.Advances in the antitumor activity of dihydro-artemisinin[J].J Guangxi Univ Tradit Chin Med(广西中医药大学学报),2012,15(3):72-74.
    [4]
    Davis B,Ladner J,Sams K,et al.Artemisinin-based combination therapy availability and use in the private sector of five AMFm phase 1 countries[J].Malar J,2013,12(5):646-654.
    [5]
    Lu T,Zhang JW,Ai FW.Advances in the drug delivery systems and formulation techniques of Artemisinins with high bioavailability[J].Chin Tradit Pat Med(中成药),2015,37(1):180-183.
    [6]
    Zhang YH,Wang LJ,Gan LL,et al.Advances in the preparation and clinical application of artemether[J].Chongqing Med(重庆医学),2014,29:3967-3970.
    [7]
    Shen S,Liu SZ,Du MB.Overview of the antimalarial agents of artemisinins[J].Chin J Inf Tradit Chin Med(中国中医药信息杂志),2015,22(10):125-128.
    [8]
    Vries PJ,Diet TK.Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria[J].Drugs,1996,52(6):818-836.
    [9]
    Shahzad Y,Sohail S,Arshad MS,et al.Development of solid dispersions of artemisinin for transdermal delivery[J].Int J Pharm,2013,457(1):197-205.
    [10]
    Jain K,Sood S,Gowthamarajan K.Optimization of artemether-loaded NLC for intranasal delivery using central composite design[J].Drug Deliv,2015,22(7):940-954.
    [11]
    Kakran M,Sahoo NG,Li L,et al.Dissolution enhancement of artemisinin with β-cyclodextrin[J].Chem Pharm Bull,2011,59(5):646-652.
    [12]
    Wang B,Liu GM.The role of patents in international competition:from the lessons and experiences of artemisinin[J].China Invention Patent(中国发明与专利),2011(7):42-45.
    [13]
    Ye ZG.What brought from patent:review and reflection in the development of artemisinins antimalarial agents[J].China Invention Patent(中国发明与专利),2011(7):21-23.
    [14]
    Cui FD.Pharmaceutics(药剂学)[M].2nd ed.Beijing:Chinese Medical Science and Technology Publishing House.2011:15.
    • Related Articles

  • Related Articles

    [1]LI Hongxue, ZHANG Lei. Analysis of patent applications of heterocyclic compounds in China Pharmaceutical University 2010-2014[J]. Journal of China Pharmaceutical University, 2016, 47(2): 247-250. DOI: 10.11665/j.issn.1000-5048.20160220
    [2]MAO Dan. Patent analysis of pharmaceutical cocrystals technology in China[J]. Journal of China Pharmaceutical University, 2015, 46(4): 509-512. DOI: 10.11665/j.issn.1000-5048.20150421
    [3]WANG Jingjing, WANG Huiyan, ZHANG Lingling, XIAO Jing, HU Weiguo, ZHANG Caixia, ZHOU Jie. Technical analysis of low molecule weight heparins patents and R&D suggestions[J]. Journal of China Pharmaceutical University, 2015, 46(4): 504-508. DOI: 10.11665/j.issn.1000-5048.20150420
    [4]X-Ray Diffraction Fourier Fingerprint Pattern Analysis for Qingkailing Patent Medicine[J]. Journal of China Pharmaceutical University, 2004, (2): 41-43.
    [5]Study on Related Substances and Stability of Ceftazidime and its Preparation[J]. Journal of China Pharmaceutical University, 2002, (2): 35-38.
    [6]System Separation of Cyclosporin A Triple Therapeutic Drugs by Micellar Electrokinetic Capillary Chromatography and Evaluation of Optimal Method Ruggedness[J]. Journal of China Pharmaceutical University, 1999, (5): 373-376.
    [7]HPLC Analysis of Metoprolol and Its Metabolites in the Perfusates[J]. Journal of China Pharmaceutical University, 1997, (6): 31-35.
    [8]NMR Analysis of Bromocriptine Mesilate Tenoxicam[J]. Journal of China Pharmaceutical University, 1997, (5): 33-35.
    [9]Studies on the Synthesis and Analysis of Impurities and Decomposition Product of Ondansetron Hydrochlorid[J]. Journal of China Pharmaceutical University, 1997, (4): 8-10.
    [10]The Preparation and Analysis of New Sweetener L-Asp-D-Ala-OiPr[J]. Journal of China Pharmaceutical University, 1997, (2): 114-115.

Catalog

    Get Citation
    PDF
    XML
    Article views (1230) PDF downloads (2859) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：414987

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return